Download CENTRE FOR CANCER BIOMEDICINE

CENTRE FOR
CANCER
BIOMEDICINE
ANNUAL REPORT
2007
CENTRE FOR
CANCER
BIOMEDICINE
2
TABLE OF CONTENTS
SUMMARY .............................................................................................................................. 3
SCIENTIFIC ACTIVITY REPORT..................................................................................... 4
PRIZES, AWARDS and PROMOTIONS......................................................................... 8
MEDIA COVERAGE ........................................................................................................... 12
CCB PUBLICATIONS ........................................................................................................ 13
PRESENTATIONS .............................................................................................................. 16
ABOUT CCB......................................................................................................................... 17
PERSONNEL AND RECRUITMENT ............................................................................... 18
FUNDING AND COSTS.................................................................................................... 21
CENTRE FOR
CANCER
BIOMEDICINE
3
SUMMARY
Centre for Cancer Biomedicine (CCB) was officially opened on 1st September 2007. Dedicated to
the unification of basic and translational cancer research, the main asset of this centre, but also its
most important challenge, is the seamless collaboration across the disciplines of cell biology,
translational cancer research and biostatistics. Therefore, during the opening phase of the centre,
much effort has been put into the planning and implementation of joint activities such as joint
thematic seminars and interdisciplinary research projects. A centre webpage has also been
established (www.ccb.uio.no). While the outcome of these efforts in terms of publications should
become evident in a couple of years, it is clear that they are already having a positive impact on
the scientific activity within the centre. Even though CCB has only been running for a few months,
several important CCB papers have already been published. These include mechanistic insight into
autophagy (“self-eating”), a cellular process that may have both tumour suppressive and tumour
promoting functions, and the identification of a novel prospective biomarker for colorectal cancer,
MAL. That CCB scientists are highly ranked among their peers is illustrated by several awards in
2007, including honorary doctorships to Kirsten Sandvig and Sjur Olsnes, the award of H.M. King
Olav’s prize for excellent cancer research to Ragnhild Lothe, the award of Medinnova’s innovation
prize to Ragnhild Lothe, Guro Elisabeth Lind, Rolf Skotheim and Terje Ahlquist, and the award of
the Mørk’s legazy prize to Anne Simonsen. The first M.Sc. and Ph.D. candidates have graduated
from CCB already, Ellen Røyrvik and Karine Lindmo. In conclusion, CCB got a head start in 2007,
and there is a lot of enthusiasm to drive the successful execution of the centre project in the years
to come.
Drosophila eye disk
Drosophila egg chamber
CENTRE FOR
CANCER
BIOMEDICINE
4
SCIENTIFIC ACTIVITY REPORT
2007
Centre for Cancer Biomedicine (CCB) was officially opened on 1st September 2007. However, the
scientific work of the centre was initiated as soon as the centre status was announced. In this
report, publications listing CCB as affiliation are included even if some of these were published
prior to 1st September. As many as 25 papers in international journals were published by CCB last
year, demonstrating a high activity in the centre’s founding year.
Although interdisciplinary collaborations lie at the heart of the centre project, it is clear that it will
require some time to develop and consolidate such collaborations, and the publications arising
from these will only appear in a couple of years’ time. In the meantime, it is pleasing to observe
that the individual groups of CCB are involved in high-quality cancer research. Lothe’s group
performs genetic and epigenetic studies of colorectal cancer, testis cancer, malignant peripheral
nerve sheath tumours and prostate cancer. This group is already providing promising biomarkers
for cancer (see below). Danielsen’s group uses genetics and advanced imaging to study prostate
cancer, and to improve its diagnostics. Smeland’s group studies lymphomas and lymphocytes
using both cell biological and genetic methods. Olsnes’ group has detected a novel mode of
signalling by fibroblast growth factors and is interested in such signalling in the context of
carcinogenesis. Sandvig’s group studies intracellular transport mechanisms in cells and more
specifically how protein toxins enter cells, with the goal of understanding cancer and improving
treatment. Stenmark’s group focuses on autophagy and endocytic downregulation of growth factor
receptors, and the importance of these mechanisms in tumour suppression. Liestøl’s group
develops novel biostatistical methods and applies them to study data from population studies,
gene expression analyses and molecular imaging. While the research of the individual groups has
been proceeding well, as documented by the list of publications, the vision of CCB is to generate
an added value through novel collaborations across the disciplines of translational cancer research,
biostatistics and cell biology. During the centre’s founding year, several such collaborations have
been initiated, which will hopefully yield results of significance for cancer research and diagnostics
within a few years.
One of the highlights from last year was the identification of the MAL gene as a prospective
biomarker for early detection of colorectal cancer (Lind et al, Gastroenterology, 2007). Promoter
hypermethylation of MAL was shown to be present in the vast majority of colorectal adenomas and
carcinomas and only rarely in normal mucosa. This places MAL as a promising early diagnostic
marker, and further studies within CCB will not only validate the utility of MAL as a diagnostic
marker but also seek to clarify the functions of MAL and their possible relevance to oncogenesis.
Moreover, the methodology used to identify hypermethylation of MAL will be used to screen for
additional prospective biomarkers in colorectal cancer as well as other cancers focused by the
centre.
CENTRE FOR
CANCER
BIOMEDICINE
5
One of the CCB-focused cancers, lymphoma, arises from lymphocytes, and a key activity in the
centre will be to identify biomarkers that distinguish lymphoma cells from normal lymphocytes. In
this context it is important to characterize gene expression patterns during normal lymphocyte
development. CCB researchers have now characterized the early stages of human B lymphocyte
development by gene expression profiling (Hystad et al., J.Immunol. 2007). Hierarchical clustering
of 758 differentially expressed genes clearly separated hemopoietic stem cells, early B, pro-B, preB, and immature B cells. In future research at CCB, comparison of gene expression profiles of
normal and neoplastic B cell progenitors may identify genes involved in the oncogenic
transformation and gene products of potential prognostic and therapeutic relevance.
Two membrane trafficking pathways, endocytosis and autophagy, are of special interest in cancer
research. Endocytosis mediates downregulation of growth factor receptors, thereby potentially
serving a tumour suppressor function. Autophagy serves to degrade damaged organelles,
including those producing DNA-damaging oxygen radicals, and therefore has a tumour suppressor
function. On the other hand, autophagy may also enable tumours to survive by providing them a
source of amino acids. Recent research at CCB has shed light on the molecular mechanisms of
both endocytic receptor downregulation and autophagy. In fact, CCB scientists were able to show
that these two pathways interact (Rusten et al., Curr.Biol. 2007), a finding that was highlighted
under “Leading Edge” in Cell. In future work it will be interesting to investigate possible
correlations between the endocytic and autophagic machineries and oncogenesis, taking
advantage of the multidisciplinary expertise of the centre.
CCB scientists have also been active in writing reviews and commentary articles in 2007. Of
special interest is a review article on aberrant receptor signalling and trafficking as mechanisms in
oncogenesis (Haglund et al., Crit.Rev.Oncogen. 2007), since this review is very relevant to the
prospective collaborative projects of CCB. Recent commentaries in leading journals (Rusten and
Stenmark, Nature, 2007; Simonsen and Stenmark, Nat.Chem.Biol., 2007) have served to discuss
novel aspects of autophagy and receptor trafficking, but have also contributed to place CCB on the
cancer research map.
In conclusion, even though CCB still is in its infancy, the scientific activity within the centre is
already at an advanced level, and several projects stand out as promising areas for collaborative
efforts. A key challenge in the years to come will be to improve the scientific standard even
further by utilizing the potential represented by the complementary expertise of the centre
scientists.
CENTRE FOR
CANCER
BIOMEDICINE
6
EDUCATION AND INTERACTION ACTIVITY
The scientific work of the centre was initiated as soon as the centre status was announced in
January 2007. So were the centre activities, directed towards the unification of basic and
translational cancer research and interdisciplinary research projects. These efforts of 2007 were
manifested in the below list of seminars.
CCB kick-off seminar at Soria Moria, May 7th-8th
This was primarily a teambuilding seminar, with focus on
ƒ
the main goals of CCB
ƒ
CCB research programmes
ƒ
presentations by the group leaders
ƒ
group work on how to define and approach the challenges of CCB
ƒ
CoE experience by CMBN (Centre for Molecular Biology and Neuroscience), Tonje Tønnum
ƒ
Intellectual property rights, by Harald Dugstad, Medinnova
ƒ
social gathering
The seminar was very successful in increasing the spirits and the consciousness of CCBs aims and
vision. Scientists within the centre, but from different disciplines got to know each other better.
The speakers, as well as the audience, were very enthusiastic when presenting and discussing
CCB matters! From top left: Harald Stenmark/Chema Bassols, Maria Lyngaas Torgersen, Tonje
Tønnum, Knut Liestøl, CCB, CCB and Sjur Olsnes/Håkon Wæhre.
CENTRE FOR
CANCER
BIOMEDICINE
7
Start-up seminar and establishment celebration, November 9th at Hotel Plaza.
This was a lunch seminar, taking CCB one step further against practical implementation of actions
discussed in the previous seminar (Soria Moria).
CCBs speakers as well as ‘actors’ got the chance to expose their innovative talents! From top left:
Ragnhild Lothe (1st and 2nd picture), Harald Stenmark. CCB audience and CCB ubiquitin ‘actors’.
Thematical seminars
CCB started in 2007 an internal seminar series with primarily two purposes; One to stimulate
interrelationships between people from different research groups by arranging the seminars
together, and the other pure educational. The first seminar was held on December 10th on the
theme: Colorectal cancers; disease, tumour etiology, clinical and biomedical challenges.
The series has continued with monthly seminars in 2008.
CENTRE FOR
CANCER
BIOMEDICINE
8
PRIZES, AWARDS and PROMOTIONS
Medinnova's Idea Prize to CCB research group working on early markers for tumors in
the digestive system
Every year Medinnova distributes its Idea prize
to the best idea with commercial potential
originating from employees belonging to the
Norwegian Health Region South-East (Helse SørØst).
This years prize went to four employees from the
Department of Cancer Prevention, Centre for
Cancer Biomedicine (photo): Rolf I. Skotheim,
Terje Ahlquist, Guro E. Lind and Ragnhild A.
Lothe.
They have identified new biological markers for
colorectal
tumours.
These
markers
may
contribute to the development of a test for
discovering cancer at an early stage.
Dr. Ragnar Mørk legacy prize to Anne Simonsen
This year's prize from "Dr. Ragnar Mørk legacy" was awarded Anne
Simonsen from the Department of Biochemistry, Centre for Cancer
Biomedicine, at the Norwegian Radium Hospital.
The "Dr. Ragnar Mørk legacy" prize is distributed annually to a scientist
who has achieved excellent results throughout years of outstanding
research.
The ceremony took place in the seminar room at the Institute for Cancer
Research on Friday 22nd of November. Simonsen gave a lecture
summarizing her work.
CENTRE FOR
CANCER
BIOMEDICINE
9
Centre of Cancer Biomedicine group leader, Sjur Olsnes, promoted honorary doctor at
the Moscow Medical Academy
Sjur Olsnes was in 2007 appointed honorary doctor at the Sechenov Academy in
Moscow. He received the honor for his contributions to Russian medical research.
His activities include establishing a centre for medical studies, as well as
encouraging scientific cooperation between Russian and Norwegian research
groups.
The Sechenov Academy is the largest and oldest medical university in Moscow, as well as in
Russia.
Sjur Olsnes and Frode Lærum have cooperated with the Sechenov Academy since 1993. Activites
they have introduced include exchange of students, supplementary training for medical doctors
through joint seminars with Norwegian and Russian physicians, and supporting research of
common interest.
A close contact between the medical faculty at the University of Oslo and the Sechenov academy
has developed through the years.
Olsnes and Lærum have created a Centre for Medical Studies in Moscow, a place with competent
offices and good infrastructure. The centre supports a number of research fellows, and is working
for establishing contact with Norwegian research groups, with a view to scientific cooperation
Centre of Cancer Biomedicine group leader, Kirsten Sandvig, promoted honorary doctor
at The University of Copenhagen
Kirsten Sandvig was Nov. 15th promoted honorary doctor at the Medical Faculty, University of
Copenhagen (Doctor Medicinae Honoris Causa). The promotion took place at the annual
Commemoration Ceremony of the University.
HRH Queen Margrethe II and HRH Prince Henrik were both present and
greeted the honorary doctors. The ceremony was followed by a reception
and a gala performance of La Boheme in the Copenhagen Opera House.
The main reasons for the appointment were that Kirsten Sandvig has
been important for the scientific activity at the University of Copenhagen
and that she has published more than 200 articles, many in high impact
journals.
Kirsten Sandvig has been collaborating with Bo van Deurs at the
University of Copenhagen since 1984, and the collaboration has
Kirsten
resulted in more than 90 articles.
ceremony
Sandvig
at
the
Among the scientific contributions is the early evidence for several endocytic pathways and the
CENTRE FOR
CANCER
BIOMEDICINE
10
discovery of retrograde transport from the cell surface to the Golgi and the endoplasmic reticulum,
published in Nature.
Sandvig has been visiting Copenhagen in connection with courses, meetings and seminars, for
instance in connection with the “Cell Biology Cluster” headed by Bo van Deurs. One reason for the
appointment was that the collaboration has been of great importance for many young
investigators at the University of Copenhagen. Several members of the Danish research group
have been on longer visits to Sandvigs lab in Oslo.
Rolf I. Skotheim appointed visiting professor in Finland
Rolf I. Skotheim from the Department of Cancer Prevention at the Institute for
Cancer Research has received a visiting professorship from the VTT Technical
Research Centre of Finland.
VTT is part of the "Translational Genome-Scale Biology" consortium, which is a
Finnish Centre of Excellence, led by professor Olli Kallioniemi.
Skotheim's new professorship strengthens the long-term collaboration between
his own
department - which is part of the Norwegian CoE "Centre for Cancer Biomedicine" - and the one of
Olli Kallioniemi, as well as the collaboration between the two CoEs.
Skotheim will mainly work together with a bioinformatics team, and one particular project
concerns construction and utilization of a database of genome-wide transcriptome data from
thousands of human samples. Careful biological and clinical annotation as well as normalization
across the whole sample spectrum makes this a unique resource in the cancer research field.
Rolf I. Skotheim has a PhD in cancer genetics and hands on experience in large-scale functional
genomics. He is currently leading two major projects at the Department of Cancer Prevention
“Qualitative transcript variation in solid tumours” and “Functional genomics of testicular germ cell
tumours”.
King Olav V’s prize for cancer research 2007 awarded to Centre of Cancer Biomedicine group
leader, Ragnhild A. Lothe
King Olav V's annual prize for cancer research 2007 was on June 14th awarded to Professor
Ragnhild A. Lothe from the Department of Cancer
Prevention,
Centre
for
Cancer
Biomedicine
at
the
Institute for Cancer Research, Rikshospitalet HF. King
Harald V presented Professor Lothe with this prestigious
prize, which is funded by Norwegian Cancer Society.
Ragnhild A. Lothe was recognized for her studies on the
genetics and epigenetics of human solid tumours, with
special emphasis on colorectal cancer, testicular cancer, and peripheral nerve sheath tumours. To
CENTRE FOR
CANCER
BIOMEDICINE
11
gain knowledge of the complex dynamics of cancer development her research team has combined
large-scale and detailed biology research using in vitro models and clinical samples.
Lothe's goal is to bring the obtained information into molecularly assisted diagnostics, which
ultimately may be useful for therapeutic decision-making.
Professor Ragnhild Lothe was in 2007 also elected new member of ‘The Norwegian
academy of Science and Letters’
Most of the above text in this section is copied from the webpage of Institute for Cancer Research at the Radium hospital; radium.no.
CENTRE FOR
CANCER
BIOMEDICINE
12
MEDIA COVERAGE
Some papers published by CCB researchers got special attention in 2007:
Editorial in Cell highlights paper from Rusten and co-workers, Centre for Cancer
Biomedicine.
The December 28 issue of "Cell" (impact factor 29.19) had an editorial about autophagy. Here,
recent important publications that had contributed to our understanding of this process - by
identifying new molecular players and new ways to manipulate autophagic pathways - were
discussed. Among these was an article from Tor Erik Rusten and co-workers, entitled "ESCRTs and
Fab1 regulate distinct steps of autophagy".
(from the ingress:) "The cellular process of autophagy (literally self-eating) is important during development
and in the normal physiology of an organism. During autophagy, cellular components destined for degradation
are enclosed in a double-membraned vesicle (the autophagosome), which then fuses with a lysosome where
the contents are degraded and mostly recycled. Dysregulation of autophagy occurs in many diseases including
cancer and neurodegeneration. Several recent papers contribute to our understanding of autophagy by
identifying new molecular players in this process and new ways to manipulate autophagic pathways."
Autophagy paper from ICR researchers highlighted in Science
A recent paper from Anne Simonsen and co-workers published in the journal Autophagy (impact
factor 6,7) - showing that induction of autophagy in the neurons of aging flies strongly increases
their life span - was dedicated an editorial ("Editor's choice") in the 14th December issue of
Science. Simonsen is the leader of the project group "Autophagy in health and disease" at Centre
for Cancer Biomedicine, Institute for Cancer Research (ICR).
Tor Erik Rusten and Pauline Isakson in good spirits and working hard!
Most of the above text in this section is copied from the webpage of Institute for Cancer Research at the Radium hospital; radium.no.
CENTRE FOR
CANCER
BIOMEDICINE
13
Articles on the announcement of Centre of Cancer Biomedicine as Centre of Excellence:
An article about the Minister of Knowledge visiting Harald Stenmark at Institute of Cancer
Research was published on Uniforum nett on Dec. 21st 2006. The CCB vision was cited.
Link: http://wo.uio.no/as/WebObjects/avis.woa/wa/visArtikkel?id=34645&del=uniforum
An article was published on Uniforum nett in March 2007. It is based on an interview of Harald
Stenmark and Ragnhild Lothe who describe CCB, its vision, aims and challenges.
Link: http://wo.uio.no/as/WebObjects/avis.woa/wa/visArtikkel?id=36485&del=uniforum
RCN published in September an article in their journal ‘Forskning’ (no. 3/2007), about CCB
cancer research.
Link: http://forskningsradet.ravn.no/bibliotek/forskning/200703/2007030016.html
CCB PUBLICATIONS
2007
Lind, G. E. Skotheim, R. I. Lothe, R. A. (2007)
The epigenome of testicular germ cell tumors
Apmis 115:1147-60
Nilsen T, Rosendal KR, S¸rensen V, Wesche J, Olsnes S, Wiedùocha A.
A nuclear export sequence located on a beta-strand in fibroblast growth factor-1.
J Biol Chem. 2007 Sep 7;282(36):26245-56.
Sivertsen, E. A. Huse, K. Hystad, M. E. Kersten, C. Smeland, E. B. Myklebust, J. H. (2007)
Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
Eur J Immunol 37:2937-48
Progida, C. Malerod, L. Stuffers, S. Brech, A. Bucci, C. Stenmark, H. (2007)
RILP is required for the proper morphology and function of late endosomes
J Cell Sci 120:3729-37
Hystad, M. E. Myklebust, J. H. Bo, T. H. Sivertsen, E. A. Rian, E. Forfang, L. Munthe, E. Rosenwald, A. Chiorazzi, M. Jonassen,
I. Staudt, L. M. Smeland, E. B. (2007)
Characterization of early stages of human B cell development by gene expression profiling
J Immunol 179:3662-71
Haglund, K. Rusten, T. E. Stenmark, H. (2007)
Aberrant receptor signaling and trafficking as mechanisms in oncogenesis
Crit Rev Oncog 13:39-74
Spilsberg, B. Llorente, A. Sandvig, K. (2007)
Polyunsaturated fatty acids regulate Shiga toxin transport
Biochem Biophys Res Commun 364:283-8
CENTRE FOR
CANCER
BIOMEDICINE
14
Martin-Acebes, M. A. Gonzalez-Magaldi, M. Sandvig, K. Sobrino, F. Armas-Portela, R. (2007)
Productive entry of type C foot-and-mouth disease virus into susceptible cultured cells requires clathrin and is dependent
on the presence of plasma membrane cholesterol
Virology 369:105-18
Pradhan M, Abeler VM, Danielsen HE, Risberg B. (2007)
A distinct pattern in the DNA ploidy histograms of hydatidiform moles and nonmolar abortuses is caused by accumulation
of trophoblasts in the late s-phase.
Int J Gynecol Pathol. Oct;26(4):432-6.
Kurmanova A, Llorente A, Polesskaya A, Garred O, Olsnes S, Kozlov J, Sandvig K. (2007)
Structural requirements for furin-induced cleavage and activation of Shiga toxin.
Biochem Biophys Res Commun. 2007 May 25;357(1):144-9.
Llorente A, van Deurs B, Sandvig K. (2007)
Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells.
Eur J Cell Biol. Jul;86(7):405-15.
Utskarpen A, Slagsvold HH, Dyve AB, Skånland SS, Sandvig K. (2007)
SNX1 and SNX2 mediate retrograde transport of Shiga toxin.
Biochem Biophys Res Commun. Jun 29;358(2):566-70.
Rusten TE, Stenmark H. (2007)
Developmental biology: moonlighting at the pole.
Nature. Feb 1;445(7127):497-9.
Simonsen A, Stenmark H.
Stimulating the cell's appetite for itself.
Nat Chem Biol. 2007 Jun;3(6):304-6.
Maler¸d L, Stuffers S, Brech A, Stenmark H.
Vps22/EAP30 in ESCRT-II mediates endosomal sorting of growth factor and chemokine receptors destined for lysosomal
degradation.
Traffic. 2007 Nov;8(11):1617-29. Epub 2007 Aug 20.
Rusten TE, Vaccari T, Lindmo K, Rodahl LM, Nezis IP, Sem-Jacobsen C, Wendler F, Vincent JP, Brech A, Bilder D, Stenmark H.
ESCRTs and Fab1 regulate distinct steps of autophagy.
Curr Biol. 2007 Oct 23;17(20):1817-25. Epub 2007 Oct 11.
Almstrup K, Leffers H, Lothe RA, Skakkebaek NE, Sonne SB, Nielsen JE, Rajpert-De Meyts E, Skotheim RI.
Improved gene expression signature of testicular carcinoma in situ.
Int J Androl. 2007 Aug;30(4):292-302; discussion 303.
Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA.
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.
Mol Cancer. 2007 Feb 2;6:12.
Lind GE, Ahlquist T, Lothe RA.
DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors.
Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632.
Oldenburg J, Kraggerud SM, Bryd¸y M, Cvancarova M, Lothe RA, Fossa SD.
Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-stransferase-P1 and -M1, a retrospective cross sectional study.
J Transl Med. 2007 Dec 27;5:70.
Royrvik EC, Ahlquist T, Rognes T, Lothe RA.
Slip Slidin' Away: A Duodecen-nial Review of Targeted Genes in Mismatch Repair Deficient Colorectal Cancer.
Crit Rev Oncog. 2007;13(3):229-57.
CENTRE FOR
CANCER
BIOMEDICINE
15
Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z.
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Epigenetics. 2007 Oct-Dec;2(4):237-43. .
Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE.
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and
CRABP1 as novel targets.
Mol Cancer. 2007 Jul 10;6:45.
Simonsen A., Cumming R. and Finley K.D.
Linking lysosomal trafficking defects with changes in aging and stress response in Drosophila.
Autophagy, 2007; Sep-Oct;3(5):499-501
Simonsen A., Cumming RC., Lindmo K., Galavis V., Cheng S., Rusten TE. and Finley K.D. Genetic modifiers of the Drosophila blue
cheese gene link defects in lysosomal transport with decreased life span and altered ubiquitinated-protein profiles.
Genetics. 2007; 176(2) 1283-1297
Coworkers of Centre for Cancer Biomedicine in action.
CENTRE FOR
CANCER
BIOMEDICINE
16
PRESENTATIONS
Some international meetings where CCB participants have presented their work:
Harald Stenmark:
Chairman and speaker at the subgroup meeting on “Ubiqutin as a regulator of membrane
trafficking”, ELSO congress, Dresden, Germany. (1-4.9.07)
Invited speaker and meeting vice chair of the EMBO conference on “Membrane Dynamics in
Endocytosis”, Villars, Switzerland. (18-23.09.07)
Invited speaker at the International Symposium on Membrane Trafficking, Awajishima, Japan.
(27-30.11.07)
Ragnhild Lothe:
Invited Speaker at Oncological Forum in Bergen (20-21.11.07)
Kirsten Sandvig:
Invited speaker at University of Kuopio, Finland, (29-31.10.07). Lecture: entry of protein toxins
into cells.
CENTRE FOR
CANCER
BIOMEDICINE
17
ABOUT CCB
Organization
Centre for Cancer Biomedicine (CCB) at the University of Oslo (UiO) and Rikshospitalet HF has since
st
September 1 2007 been a Centre of Excellence, appointed by the Research Council of Norway. The centre is
located at the Radium hospital, Rikshospitalet HF.
CCB is a constellation of 7 independent research groups cooperating to reach the aims of the centre. The groups
are headed by, respectively, the group leaders Harald Stenmark, Ragnhild Lothe, Sjur Olsnes, Kirsten Sandvig,
Erlend Smeland, Håvard Danielsen and Knut Liestøl/Ole Crisitian Lingjærde.
Management
CCB is headed by Harald Stenmark (director) and Ragnhild A. Lothe (vice director). Stenmark has
the daily responsibility for project management, administration and delivery (technical and
financial), assisted by administrative coordinator, Jannikke Ludt. The director collaborates closely
with the Executive Group, consisting of the additional six Principal Investigators, in scientific
matters. Lothe assists Stenmark in scientific matters and strategy and represents CCB in the
Stenmark’s absence.
Board
The centre management reports to the centre board. The board was not constituted until 2008, but the members
are:
Sigbjørn Fossum (UiO), chair
Anders Elverhøi (UiO)
Karl-Erik Giercksky (Rikshospitalet HF)
Erlend Smeland (Rikshospitalet HF)
International advisory board
An international advisory board for scientific matters will be appointed in 2008.
University of
Oslo
Rikshospitalet
Institute for
Cancer Research
Faculty
division
Radiumhospit
Faculty of
Medicine
The Research
Council of
Norway
Faculty of
Mat. Nat.
CENTRE
BOARD
International
advisory
board
CENTRE
MANAGEMENTT
Executive
group (7 group
leaders)
CENTRE FOR
CANCER
BIOMEDICINE
18
PERSONNEL AND RECRUITMENT
The centre is staffed by 94 persons, of whom 63 (67%) are women. When categorized by position,
the profile is 7 group leaders, 11 researchers (senior scientists), 23 post docs and 29 PhD
students. Technical and Administrative staff are 24 persons.
Total staff
35
Number of persons
30
25
20
15
10
5
st
ud
en
Te
ts
ch
n/
Ad
m
.S
ta
ff
Ph
D
do
cs
Po
st
es
ea
rc
he
rs
R
G
ro
up
le
ad
er
s
0
The persons participating in Centre for Cancer Biomedicine in 2007 were (blue print: Funded by
the CCB grant):
List of CCB
employees,
2007
Name
Position
Group
Ahlquist, Terje
Alagaratnam,
Sharmini
Andersson, Sofia
Bakkebø, Maren
PhD student
Postdoc,
Lothe
Lothe
Norway
Malaysia
RHF from 12.11.07
Rikshospitalet HF
MSc
PhD
Postdoc
Stipendiat,
Sandvig
Smeland
Sweden
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
MSc
Bassols, Chema
Computer
specialist
PhD student
Technician
Olsnes
Spania
Rikshospitalet HF
Lothe
Olsnes
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
Project Leader,
Senior Scientist
(FUGE)
PhD student
Professor / Group
Leader
Research fellow
Stenmark
Norway
Rikshospitalet HF
PhD
Lothe
Danielsen
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
PhD
Lothe
Norway
Rikshospitalet HF
MSc
Ph.D. Student
(RCN)
Ph.D student
Sandvig
Norway
Rikshospitalet HF
MSc
Smeland
Norway
UiO
MD
Forsker
Medical
technologist
Postdoc
Lothe
Lothe
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
Sandvig
Norway
Rikshospitalet HF
PhD
Technician
Olsnes
Norway
Rikshospitalet HF
Berg, Marianne
Bergersen, Anne
Gro
Brech, Andreas
Brekke, Helge
Danielsen, Håvard
Danielsen, Stine
Aske
Dyve, Anne Berit
Eide, Marianne
Brodtkorb
Eiken, Hans Geir
Eknæs, Mette
Engedal, Kim
Nikolai
Engen, Anne
Nationality
Employer
Academic
title
CENTRE FOR
CANCER
BIOMEDICINE
Farstad,
Benedikte
Filimonenko,
Maria
Forfang, Lise
Guha, Nirmalendu
Haglund, Kaisa
Haugsten, Ellen
M.
Heggland, Grete
Hektoen, Merete
Hilden, Vera Irene
Homeide
Aagesen, Trude
Huse, Kanutte
Hveem, Tarjei
Sveinsgjerd
Isakson, Pauline
Iversen, ToreGeir
Jin, Yi-xin
Johannessen, May
Elisabeth
Kildahl, Wanja
Kjæreng, Marna
Lill
Kolberg, Matthias
Kraggerud, Sigrid
M.
Lauvrak, Silje
Anett Ugland
Lemus, Dafne
Liestøl, Knut
Lind, Guro
Elisabeth
Lindmo, Karine
Lindvall, Jessica
Lingjærde, Ole
Christian
Lobert, Viola
Lothe, Ragnhild
A.
Ludt, Jannikke
Løvig, Tone
Malecki, Jedrzej
Malerød, Lene
Merok, Marianne
Aarstad
Mjøen, Linda Uv
Myklebust, June
Helen
Myrann, Anne
Grethe
Nesheim, John
Arne
Nezis, Ioannis
Nielsen, Birgitte
Nilsgård, Siri
19
Technician (CCB)
Stenmark
Norway
Rikshospitalet HF
Ph.D. student
(University of
Oslo)
Technician,
Laboratory
assistant
Postdoc (Human
Frontier Science
Programme)
Ph.D. student
Stenmark
Norway
UiO
Smeland
Olsnes
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
Bachelor
Stenmark
Sweden
Human Frontier
Science program
PhD
Olsnes
Norway
Rikshospitalet HF
MSc
Technician
Medical
technologist
Technician
PhD student
Sandvig
Lothe
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
Smeland
Lothe
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
MSc
PhD student
Developer
Smeland
Danielsen
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
MSc
Ph.D. student
(FUGE)
Senior Scientist
(RCN)
Post doc
Secretary
Stenmark
Sweden
Rikshospitalet HF
MSc
Sandvig
Norway
Rikshospitalet HF
PhD
Olsnes
Olsnes
China
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
Ph. D student
Danielsen
Danielsen
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
Researcher
Post doc
Lothe
Lothe
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
PhD
Postdoc (Norw.
Cancer Soc.)
Ph.D. student
Professor / Group
Leader
Post doc
Sandvig
Norway
Rikshospitalet HF
PhD
Stenmark
Liestøl
Mexico
Norway
Rikshospitalet HF
UiO
MSc
PhD.
Lothe
Norway
Rikshospitalet HF
PhD
Ph.D. student
(CCB)
Post doc
Førsteamanuensis
Stenmark
Norway
Rikshospitalet HF
PhD
Liestøl
Liestøl
Sweden
Norway
UiO
UiO
PhD
PhD
Technician (the
Norwegian
Cancer Society)
Professor / Group
Leader
Administrative
coordinator,
Medical
technologist
Guest Senior
Scientist (Norw.
Cancer Soc.)
Postdoc (FUGE)
PhD student
Stenmark
France
Rikshospitalet HF
Lothe
Norway
Rikshospitalet HF
PhD
Norway
UiO
PhD
Lothe
Norway
Rikshospitalet HF
PhD
Olsnes
Poland
Rikshospitalet HF
PhD
Stenmark
Lothe
Norway
Norway
Rikshospitalet HF
Aker / RH
PhD
MD
Post doc
Smeland
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
Technician
Sandvig
Norway
Rikshospitalet HF
Developer
Danielsen
Norway
Rikshospitalet HF
Postdoc (FUGE)
Post doc
Laboratory
Stenmark
Danielsen
Olsnes
Greece
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
Rikshospitalet HF
MSc
PhD
PhD
CENTRE FOR
CANCER
BIOMEDICINE
Oksvold, Morten
Olsnes, Sjur
Pedersen, Nina
Marie
Pretorius, Maria
Pust, Sascha
Raiborg, Camilla
Ribeiro, Franclim
Ricardo da Silva
Rodahl, Lina W.
Roxrud, Ingrid
Rusten, Tor Erik
Rødland, Einar
Rønning, Eva
Røyrvik, Ellen C.
Raa, Hilde
Sagona, Antonia
Sandvig, Kirsten
Sem-Jacobsen,
Catherine
Simonsen, Anne
Skiple Skjerpen,
Camilla
Skotheim, Rolf I.
Skånland, Sigrid
Slåtta, Carina
Smeland, Erlend
Bremertun
Stenmark, Harald
Stordal Bjørklund,
Sunniva Maria
Stuffers, Susanne
Sveen, Anita
Sørensen, Vigdis
Tengs, Torstein
Tolonen Egeberg,
Nina Johanna
Torgersen, Maria
Lyngaas
Utskarpen,
Audrun
Wesche, Jørgen
Wiedlocha, Antoni
Wæhre, Håkon
Yadollahi,
Mandana
Zakrzewska,
Malgorzata
Zhen, Yan
20
assistant
Post doc
Group leader,
Professor,
dr.med.
Postdoc (Helse
Sør)
Ph.D student
Postdoc
Postdoc (the
Norwegian
Cancer Society)
Post doc
Smeland
Olsnes
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
PhD
MD, PhD
Stenmark
Norway
Rikshospitalet HF
PhD
Danielsen
Sandvig
Stenmark
Norway
Germany
Norway
Rikshospitalet HF
Rikshospitalet HF
Rikshospitalet HF
MSc
PhD
PhD
Lothe
Portugal
Ph.D. student
(EMBIO)
Ph.D. student
(RCN)
Postdoc (FUGE)
Post doc
Head technician
Research fellow
Ph.D. student
Ph.D. student
(EU)
Professor / Group
Leader
PhD student (the
Norwegian
Cancer Society)
Project Leader,
Senior Scientist
(the Norwegian
Cancer Society)
Post doc
Stenmark
Norway
UiO
MSc
Stenmark
Norway
Rikshospitalet HF
MSc
Stenmark
Liestøl
Stenmark
Lothe
Sandvig
Stenmark
Norway
Norway
Norway
Norway
Norway
Norway
Rikshospitalet
NR
Rikshospitalet
Rikshospitalet
Rikshospitalet
Rikshospitalet
PhD
PhD
HF
HF
HF
HF
MSc
MSc
MSc
Sandvig
Norway
Rikshospitalet HF
PhD
Stenmark
Norway
Rikshospitalet HF
MSc
Stenmark
Norway
Rikshospitalet HF
PhD
Olsnes
Norway
Rikshospitalet HF
PhD
Project leader,
senior scientist
Ph.D. student
Laboratory
Assistant
Professor / Group
Leader
Professor / Group
Leader
Ph.D. student
Lothe
Norway
Rikshospitalet HF
PhD
Sandvig
Olsnes
Norway
Norway
Rikshospitalet HF
Rikshospitalet HF
MSc
Smeland
Norway
Rikshospitalet HF
MD, PhD
Stenmark
Norway
UiO
PhD
Olsnes
Norway
Rikshospitalet HF
MSc
PhD student
(FUGE)
PhD student
Post doc
Post doc
Technician
(FUGE)
Postdoc
Stenmark
Norway
Rikshospitalet HF
MSc
Lothe
Olsnes
Danielsen
Stenmark
Norway
Norway
Norway
Finland
Rikshospitalet
Rikshospitalet
Rikshospitalet
Rikshospitalet
HF
HF
HF
HF
MSc
PhD
PhD
Sandvig
Norway
Rikshospitalet HF
PhD
Ph.D. student
Sandvig
Norway
Rikshospitalet HF
MSc
Project Leader,
Senior Scientist
(Norw. Cancer
Soc.)
Project Leader,
Senior Scientist
Senior scientist
Laboratory
Assistant
Post doc
Olsnes
Norway
Rikshospitalet HF
PhD
Olsnes
Norway
Rikshospitalet HF
PhD
Danielsen
Olsnes
Norway
Rikshospitalet HF
Rikshospitalet HF
MD, PhD
Olsnes
Norway
Rikshospitalet HF
PhD
Ph.D. student
Olsnes
Norway
PhD
HF
MSc
CENTRE FOR
CANCER
BIOMEDICINE
21
FUNDING AND COSTS
The total income of CCB from Sept 1st 2007 was 21 744 thousand NOK. The funding was
distributed on different sources, as the chart indicates.
Own funding covers support from the host institution (UiO) and the consortium participant
Rikshospitalet HF, and includes salary, location and running costs.
CoE funding is the CCB funding provided by Research Council of Norway (3401 kNOK)
Other funding is from public and private CCB sources, including FUGE and grants from The
Norwegian Cancer society.
TOTAL FUNDING 2007
X 1000 NOK
12000
9298
9045
10000
8000
6000
3401
4000
2000
0
Own funding
CoE funding
Other
public/private
The total costs for CCB during the four months from Sept. 1st were 20 520 kNOK. Salary,
including social costs contributed to this with 14 351 kNOK. Indirect costs include premises and
infrastructure and were estimated to 5 715 kNOK. 2 172 kNOK were invested in scientific
equipment.
EXPENDITURES
X 1000 NOK
20000
15000
14351
10000
5715
5000
2172
424
0
Salary
Indirect
Equipment
Running
costs
CENTRE FOR
CANCER
BIOMEDICINE
22
CCB
Centre for Cancer Biomedicine
Norwegian Radium hospital
Montebello N-0310 Oslo
Phone: +47 22934292
[email protected]
www.ccb.uio.no